C1 Esterase Inhibitor (Berinert)

Covered: Berinert is approved for treatment of acute attacks and compendial prophylaxis of hereditary angioedema due to C1‑INH deficiency (Type I or II) and does not cover HAE with normal C1‑INH (HAE‑nC1‑INH). Key requirements: baseline labs documenting functional C1‑INH <50% and low serum C4, prescription by or consult with an HAE specialist, weight‑based dosing (20 IU/kg IV) with weight documentation, documented clinical benefit for reauthorization, and 12‑month authorization periods.

"Berinert (C1 esterase inhibitor [human]) is indicated for the treatment of acute attacks of Hereditary Angioedema (HAE)."

Sign up to see full coverage criteria, indications, and limitations.